Loading...
Older age confers added risk for mortality after acute myocardial infarction (AMI); however, randomized, controlled trials of lipid-lowering therapy after AMI have typically excluded patients in the oldest age category of 80 years and older. Using data from a nationwide registry of adults discharged after AMI in France, researchers analyzed the association between prescription of high-intensity lipid-lowering therapy (atorvastatin ≥40 mg or equivalent, or any combination of statin plus ezetimibe) and 5-year mortality in patients aged ≥80 years.
Among 2258 patients included in the study (mean age, 85±4 years; 51% women), 5-year survival rates were as follows, based on the status and intensity of lipid-lowering therapy at discharge:
No lipid-lo…